Incredible news for Canadian patients suffering from the most common form of skin cancer, and the most frequently occurring cancer of all cancers worldwide, Basal Cell Carcinoma.
Libtayo® (cemiplimab) is now approved in Canada for the treatment of adults with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI).Thank you to everyone who participated in our patient survey submission to help make this possible! Read more here
